NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 230 filers reported holding NOVOCURE LTD in Q3 2023. The put-call ratio across all filers is 0.71 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $210 | -100.0% | 3,498 | -58.7% | 0.02% | -76.1% |
| Q2 2022 | $588,000 | +142.0% | 8,462 | +288.0% | 0.09% | +114.6% |
| Q3 2020 | $243,000 | +20.3% | 2,181 | -9.1% | 0.04% | +70.8% |
| Q4 2019 | $202,000 | -37.5% | 2,400 | -44.4% | 0.02% | -45.5% |
| Q3 2019 | $323,000 | -70.4% | 4,320 | -75.0% | 0.04% | -63.9% |
| Q2 2019 | $1,092,000 | +2.4% | 17,265 | -22.0% | 0.12% | +13.0% |
| Q1 2019 | $1,066,000 | +167.8% | 22,136 | +86.0% | 0.11% | +134.8% |
| Q4 2018 | $398,000 | -74.0% | 11,900 | -59.2% | 0.05% | -45.9% |
| Q3 2018 | $1,530,000 | -1.2% | 29,200 | -41.0% | 0.08% | +10.4% |
| Q2 2018 | $1,549,000 | +248.1% | 49,500 | +142.6% | 0.08% | +220.8% |
| Q1 2018 | $445,000 | -21.7% | 20,400 | -27.4% | 0.02% | -31.4% |
| Q4 2017 | $568,000 | +18.8% | 28,100 | +16.6% | 0.04% | +6.1% |
| Q3 2017 | $478,000 | +49.4% | 24,100 | +68.5% | 0.03% | +106.2% |
| Q4 2015 | $320,000 | – | 14,300 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
| Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
| HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
| GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
| Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
| Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
| HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
| HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
| Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |